

INSERT:

LEAFLET

TELMi 40 AMH	TELMi 80 AMH	
Telmisartan + Amlodipine + Hydrochlorothiazide Tablets		
COMPOSITION:		
TELMi-40AMH: Each film coated tablet contains: Telmisartan B.P. 40 mg, Amlodipine Besilate B.P. eq. to Amlodipine 5 mg and Hydrochlorothiazide B.P. 12.5 mg		
TELMi-80AMH: Each film coated tablet contains: Telmisartan B.P. 80 mg, Amlodipine Besilate B.P. eq. to Amlodipine 5 mg and Hydrochlorothiazide B.P. 12.5 mg		
INDICATIONS: TELMi-40AMH/TELMi-80AMH is indicated for the treatment of hypertension.		
CONTRAINDICATIONS: Hypersensitivity to Telmisartan and Hydrochlorothiazide. Hypersensitivity to Amlodipine Besylate or other Calcium channel blockers. Patients with anuria, pregnant and lactating females and hereditary or idiopathic angioedema. Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs		
DOSAGE AND ADMINISTRATION: The recommended dosage is one tablet once daily and may be administered with or without food. Therapy should be individualized according to goal of therapy and response. Patients with Renal Impairment: The usual regimens of therapy with TELMi-40AMH/TELMi-80AMH may be followed as long as the patient's creatinine clearance is more than 30 ml/min. In patients with more severe renal impairment, TELMi-40AMH/TELMi-80AMH is not recommended. Patients with Hepatic Impairment: TELMi-40AMH/TELMi-80AMH is not recommended for patients with severe hepatic impairment. Patients with biliary obstructive disorders or hepatic impairment should have treatment started under close medical supervision.		
UNDESIRABLE EFFECTS: The combination of Telmisartan/ Hydrochlorothiazide/ Amlodipine is generally well tolerated. The most frequent clinical adverse effects in patients treated with this combination are fatigue, dizziness, diarrhea, nausea, back pain, dyspepsia, vomiting, hypokalemia, bronchitis, rash and postural hypotension. Other rare events included paresthesias, anorexia, sexual dysfunction, nocturia.		
IDENTIFICATION: TELMi 40AMH: Orange coloured round shape, biconvex, film coated tablet, breakline on one side and other side plain. TELMi 80AMH: Yellow coloured round shape, biconvex, film coated tablet, breakline on one side and other side plain.		
PRESENTATION: TELMi 40AMH: Jar pack of 30 tablets and Alu-alu Blisters pack of 3 x 10/1 x 10 tablets. TELMi 80AMH: Jar pack of 30 tablets and Alu-alu Blisters pack of 3 x 10/1 x 10 tablets.		
STORAGE INSTRUCTIONS: Store below 25 °C. Keep out of reach of children.		
NAME AND ADDRESS OF APPLICANT M/S Prism Life Sciences Ltd. 122, Ravi Industrial Estate, Billeshwarpura, Chhatral, Gandhinagar – 382729, Gujarat		